𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Tyrosine kinase inhibitor therapy for systemic sclerosis: Quo Vadis?

✍ Scribed by Fabian A. Mendoza; Sergio A. Jiménez

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
51 KB
Volume
63
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Current event-free survival after sequen
Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia
✍ Aref Al-Kali; Hagop Kantarjian; Jianqin Shan; Roland Bassett; Alfonso Quintás-Ca 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 297 KB

## Abstract ## BACKGROUND: Imatinib is an effective tyrosine kinase inhibitor (TKI) for patients with chronic myeloid leukemia (CML) in chronic phase (CP). Although some patients may fail on therapy with imatinib, effective salvage therapy is available with second‐generation TKIs. Current measurem

Practical advice for determining the rol
Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia
✍ Elias Jabbour; Susan Branford; Giuseppe Saglio; Dan Jones; Jorge E. Cortes; Hago 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 288 KB 👁 1 views

## Abstract Data demonstrating the superiority of nilotinib over imatinib in the frontline treatment of chronic myeloid leukemia (CML) and ongoing studies with dasatinib and bosutinib are rapidly changing the treatment landscape for CML. In this review, the authors discuss currently available thera

Novel tyrosine kinase inhibitor therapy
Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia : No evidence for increased transplant-related toxicity
✍ Elias Jabbour; Jorge Cortes; Hagop Kantarjian; Sergio Giralt; Borje S. Andersson 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 1 views

## Abstract ## BACKGROUND. Patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML) are increasingly likely to have received a novel tyrosine kinase inhibitor (NTKI) after failing imatinib mesylate. It is unknown whether the use of these NTKI

Structural modeling of V299L and E459K B
Structural modeling of V299L and E459K Bcr-Abl mutation, and sequential therapy of tyrosine kinase inhibitors for the compound mutations
✍ Dongho Kim; Dong-Wook Kim; Byung-Sik Cho; Hyun-Gyung Goh; Soo-Hyun Kim; Wan-Seok 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 592 KB

Sequential treatment with different tyrosine kinase inhibitors (TKIs) is one of the strategies for handling chronic myeloid leukemia (CML) in which dynamic change in Bcr-Abl kinase domain mutation is often an obstacle faced during TKI therapy. Here we report successful sequential therapy with differ